Latest period
$391.51M
YoY change
+73.5%
5Y CAGR
+55.1%
Peak year (2025)
$346.18M
Latest annual
$346.18M
Total Equity history chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: $346.18M
Total Equity growth chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: +73.5%
Total Equity history table for Tango Therapeutics (TNGX) from 2019 to 2025
| 2025 | $346.18M | +73.5% | +$146.66M | ||
| 2024 | $199.52M | -21.2% | −$53.59M | ||
| 2023 | $253.11M | +1.5% | +$3.63M | ||
| 2022 | $249.48M | -27.6% | −$95.27M | ||
| 2021 | $344.75M | +793.1% | +$306.15M | ||
| 2020 | $38.60M | +388.3% | +$30.70M | ||
| 2019 | $7.91M | — | — |
- 2025$346.18M+73.5%
- 2024$199.52M-21.2%
- 2023$253.11M+1.5%
- 2022$249.48M-27.6%
- 2021$344.75M+793.1%
- 2020$38.60M+388.3%
- 2019$7.91M—
Total Equity values are taken from Tango Therapeutics's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Tango Therapeutics (TNGX)
According to Tango Therapeutics's latest reported financial statements, the company's latest reported total equity is $391.51M. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Tango Therapeutics (TNGX) most recent annual total equity stands at $346.18M (2025) – surged 73.5% year-over-year.
Across 2020–2025 (5 years), Tango Therapeutics total equity produced a CAGR of +55.1% – with mixed annual results across the window.
The highest annual total equity of $346.18M was reported in 2025. The lowest in the available history was $7.91M in 2019.
Tango Therapeutics Total Equity by Year
Tango Therapeutics Total Equity 2025: $346.18M
2025's total equity for Tango Therapeutics came in at $346.18M, surged 73.5% from 2024. This figure represents the highest annual value in the available history.
Tango Therapeutics Total Equity 2024: $199.52M
Tango Therapeutics posted total equity of $199.52M in 2024, declined 21.2% below 2023.
Tango Therapeutics Total Equity 2023: $253.11M
In 2023, Tango Therapeutics reported total equity of $253.11M, edged up 1.5% from 2022.
Tango Therapeutics Total Equity 2022: $249.48M
Tango Therapeutics total equity in 2022 was $249.48M, declined 27.6% below 2021.
Tango Therapeutics Total Equity 2021: $344.75M
Tango Therapeutics total equity in 2021 was $344.75M.
See more financial history for Tango Therapeutics (TNGX).
Sector peers by Total Equity
Healthcare peers of Tango Therapeutics (TNGX), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation